Fore Pharmas latest report ‘Global Idiopathic Pulmonary Fibrosis Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global idiopathic pulmonary fibrosis drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the idiopathic pulmonary fibrosis drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Idiopathic Pulmonary Fibrosis: Overview
- Idiopathic Pulmonary Fibrosis Drug Pipeline Overview
- Idiopathic Pulmonary Fibrosis Phase 3 Clinical Trial Drug Pipeline Insights
- Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial Drug Pipeline Insights
- Idiopathic Pulmonary Fibrosis Phase 1 Clinical Trial Drug Pipeline Insights
- Idiopathic Pulmonary Fibrosis Preclinical Research Drug Pipeline Insights
- Idiopathic Pulmonary Fibrosis Drug Discovery Pipeline Insights
- Geographic Landscape of Idiopathic Pulmonary Fibrosis R&D Activities
- Idiopathic Pulmonary Fibrosis R&D Activities in North America
- Idiopathic Pulmonary Fibrosis R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Idiopathic Pulmonary Fibrosis Drug Market

1. Idiopathic Pulmonary Fibrosis: Disease Definition
2. Idiopathic Pulmonary Fibrosis Drug Pipeline Overview
3. Idiopathic Pulmonary Fibrosis Phase 3 Clinical Trial Drug Pipeline Insights
4. Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial Drug Pipeline Insights
5. Idiopathic Pulmonary Fibrosis Phase 1 Clinical Trial Drug Pipeline Insights
6. Idiopathic Pulmonary Fibrosis Preclinical Research Drug Pipeline Insights
7. Idiopathic Pulmonary Fibrosis Drug Discovery Pipeline Insights
8. Geographic Landscape of Idiopathic Pulmonary Fibrosis R&D Activities
8.1 Idiopathic Pulmonary Fibrosis R&D Activities in North America
8.2 Idiopathic Pulmonary Fibrosis R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Idiopathic Pulmonary Fibrosis Drug Market
10 Research Methodology Table 1: Idiopathic Pulmonary Fibrosis Drug Pipeline: Phase 3 Clinical Trial

Table 2: Idiopathic Pulmonary Fibrosis Drug Pipeline: Phase 2 Clinical Trial
Table 3: Idiopathic Pulmonary Fibrosis Drug Pipeline: Phase 1 Molecules
Table 4: Idiopathic Pulmonary Fibrosis Drug Pipeline: Preclinical Research
Table 5: Idiopathic Pulmonary Fibrosis R&D Activities by Geography
Table 6: Idiopathic Pulmonary Fibrosis Drug Pipeline: North America
Table 7: Idiopathic Pulmonary Fibrosis Drug Pipeline: Europe
Table 8: Idiopathic Pulmonary Fibrosis Drug Pipeline: Licensing Activities

Figure 1 : Idiopathic Pulmonary Fibrosis Drug Pipeline Molecules by Stages
Figure 2 : Idiopathic Pulmonary Fibrosis R&D Activities by Geography